Home Tools
Log in
Cart

PLK

Polo-like kinase (PLK) is a highly conserved serine/threonine protein kinase with a highly homologous serine/threonine kinase domain at its N-terminus, which regulates PLK activity and subcellular dynamics at the C-terminus and targeted polo-box domain (PBD). There are many PLK family members, and there are four subtypes in the human body, namely PLK1, PLK2, PLK3, and PLK4, which play important roles in the regulation of various phases of the cell cycle.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T19664 ON1231320 1312471-39-8 98.69%
ON1231320
ON1231320 (GBO-006) is a Polo-like kinase 2 (PLK2) inhibitor.
T22288 (1E)-CFI-400437 dihydrochloride 1247000-76-5 98.36%
(1E)-CFI-400437 dihydrochloride
(1E)-CFI-400437 dihydrochloride (CFI-400437 dihydrochloride) is a selective and potent polo-like kinase 4 (PLK4) inhibitor.
T6173 BI 2536 755038-02-9 98.31%
BI 2536
BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3.
T6247 Onvansertib 1034616-18-6 98.08%
Onvansertib
Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher o...
T1839 Mps1-IN-2 1228817-38-6 98.07%
Mps1-IN-2
Mps1-IN-2 is a potent, selective and ATP-competitive dual Mps1/Plk1 inhibitor.
T6019 Volasertib 755038-65-4 98.04%
Volasertib
Volasertib (BI 6727) (BI-6727) is a potent inhibitor of PLK1 (IC50: 0.87 nM), inducing mitotic arrest and apoptosis. It also inhibits PLK2/PLK3 (IC50s: 5/56 nM)....
T7200 TAK-960 1137868-52-0 98%
TAK-960
TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.
T10215 AAPK-25 2247919-28-2 97.79%
AAPK-25
AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in prometaphase, followed by...
T7384 Ocifisertib(CFI-400945 free base) 1338806-73-7 97.56%
Ocifisertib(CFI-400945 free base)
CFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM).
T16750 Rigosertib 592542-59-1 97.33%
Rigosertib
Rigosertib (ON-01910) is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer a...
T2704 MLN0905 1228960-69-7 97.17%
MLN0905
MLN0905 (PLK1 Inhibitor) is an effective PLK1 inhibitor(IC50=2 nM).
T2634 Ro3280 1062243-51-9 98%
Ro3280
Ro3280 (Ro5203280) is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM).
T6282 GSK461364 929095-18-1 98%
GSK461364
GSK461364 (GSK461364A)(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.
T6283 Wortmannin 19545-26-7 98%
Wortmannin
Wortmannin (SL-2052) is the first described PI3K inhibitor with IC50 of 3 nM, with little selectivity within the PI3K family. Also blocks autophagosome formation...
ON1231320
T19664
ON1231320 (GBO-006) is a Polo-like kinase 2 (PLK2) inhibitor.
(1E)-CFI-400437 dihydrochloride
T22288
(1E)-CFI-400437 dihydrochloride (CFI-400437 dihydrochloride) is a selective and potent polo-like kinase 4 (PLK4) inhibitor.
BI 2536
T6173
BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3.
Onvansertib
T6247
Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher o...
Mps1-IN-2
T1839
Mps1-IN-2 is a potent, selective and ATP-competitive dual Mps1/Plk1 inhibitor.
Volasertib
T6019
Volasertib (BI 6727) (BI-6727) is a potent inhibitor of PLK1 (IC50: 0.87 nM), inducing mitotic arrest and apoptosis. It also inhibits PLK2/PLK3 (IC50s: 5/56 nM)....
TAK-960
T7200
TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.
AAPK-25
T10215
AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in prometaphase, followed by...
Ocifisertib(CFI-400945 free base)
T7384
CFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM).
Rigosertib
T16750
Rigosertib (ON-01910) is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer a...
MLN0905
T2704
MLN0905 (PLK1 Inhibitor) is an effective PLK1 inhibitor(IC50=2 nM).
Ro3280
T2634
Ro3280 (Ro5203280) is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM).
GSK461364
T6282
GSK461364 (GSK461364A)(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.
Wortmannin
T6283
Wortmannin (SL-2052) is the first described PI3K inhibitor with IC50 of 3 nM, with little selectivity within the PI3K family. Also blocks autophagosome formation...
1 2
TargetMol